Physicochemical Properties
| Molecular Formula | C66H112N18O26S |
| Molecular Weight | 1605.76 |
| Related CAS # | LEESGGGLVQPGGSMK;2096980-79-7;LEESGGGLVQPGGSMK TFA |
| Appearance | White to off-white solid powder |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Anti-TNF antibodies obstruct the effects of TNF alpha, a novel therapy for TNF-related disorders, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, and inflammatory bowel disease. Anti-TNF antibodies stimulate mucosal healing and long-term remissions in vivo by blocking TNF activity. The primary anti-TNF antibodies that are now approved include Golimumab, Adalimumab, Certolizumab, Etanercept, and Infliximab[1]. |
| References |
[1]. A method for quantifying therapeutic antibodies. EP3371592A1. |
Solubility Data
| Solubility (In Vitro) | H2O :~100 mg/mL (~62.28 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (62.28 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6228 mL | 3.1138 mL | 6.2276 mL | |
| 5 mM | 0.1246 mL | 0.6228 mL | 1.2455 mL | |
| 10 mM | 0.0623 mL | 0.3114 mL | 0.6228 mL |